CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 1.5%

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) dropped 1.5% on Tuesday . The company traded as low as $53.26 and last traded at $54.01. Approximately 213,922 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 1,778,945 shares. The stock had previously closed at $54.83.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Morgan Stanley increased their price target on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an "underweight" rating in a research note on Monday, February 26th. Wells Fargo & Company raised their price target on CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an "equal weight" rating in a report on Thursday, February 22nd. Mizuho increased their price objective on CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a "buy" rating in a research report on Wednesday, March 6th. Royal Bank of Canada boosted their target price on CRISPR Therapeutics from $57.00 to $66.00 and gave the company a "sector perform" rating in a report on Thursday, February 22nd. Finally, Barclays boosted their price objective on shares of CRISPR Therapeutics from $61.00 to $80.00 and gave the company an "equal weight" rating in a research note on Thursday, February 22nd. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $76.29.

CRISPR Therapeutics Price Performance

The company's 50-day moving average is $69.50 and its 200-day moving average is $64.23. The firm has a market capitalization of $4.50 billion, a price-to-earnings ratio of -27.04 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.95. The company had revenue of $201.20 million during the quarter, compared to analyst estimates of $148.72 million. During the same quarter in the prior year, the company posted ($1.41) earnings per share. The firm's revenue for the quarter was up 3253.3% on a year-over-year basis. Sell-side analysts anticipate that CRISPR Therapeutics AG will post -6.24 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the business's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $80.36, for a total value of $1,607,200.00. Following the transaction, the chief executive officer now owns 187,377 shares in the company, valued at approximately $15,057,615.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Raju Prasad sold 3,524 shares of the firm's stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $72.69, for a total transaction of $256,159.56. Following the completion of the sale, the chief financial officer now owns 6,476 shares of the company's stock, valued at $470,740.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 20,000 shares of the company's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $80.36, for a total transaction of $1,607,200.00. Following the completion of the sale, the chief executive officer now directly owns 187,377 shares in the company, valued at $15,057,615.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 83,992 shares of company stock valued at $6,132,335. Corporate insiders own 4.10% of the company's stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Signaturefd LLC increased its holdings in CRISPR Therapeutics by 12.5% in the third quarter. Signaturefd LLC now owns 2,124 shares of the company's stock valued at $96,000 after buying an additional 236 shares during the last quarter. Itau Unibanco Holding S.A. raised its position in shares of CRISPR Therapeutics by 10.8% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 2,521 shares of the company's stock valued at $114,000 after acquiring an additional 245 shares in the last quarter. Spire Wealth Management lifted its stake in CRISPR Therapeutics by 32.7% during the third quarter. Spire Wealth Management now owns 1,052 shares of the company's stock worth $48,000 after purchasing an additional 259 shares during the last quarter. CWM LLC boosted its holdings in CRISPR Therapeutics by 80.7% in the third quarter. CWM LLC now owns 582 shares of the company's stock worth $26,000 after purchasing an additional 260 shares during the period. Finally, WealthPlan Investment Management LLC raised its holdings in shares of CRISPR Therapeutics by 3.1% during the fourth quarter. WealthPlan Investment Management LLC now owns 9,663 shares of the company's stock worth $605,000 after purchasing an additional 288 shares during the period. Institutional investors own 69.20% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.